X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs PIRAMAL ENTERPRISES - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS PIRAMAL ENTERPRISES IPCA LABS/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 36.4 8.9 410.0% View Chart
P/BV x 3.5 2.9 117.5% View Chart
Dividend Yield % 0.1 0.8 18.0%  

Financials

 IPCA LABS   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    IPCA LABS
Mar-17
PIRAMAL ENTERPRISES
Mar-17
IPCA LABS/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs6432,095 30.7%   
Low Rs5031,025 49.1%   
Sales per share (Unadj.) Rs254.4492.8 51.6%  
Earnings per share (Unadj.) Rs16.172.6 22.1%  
Cash flow per share (Unadj.) Rs29.894.7 31.4%  
Dividends per share (Unadj.) Rs1.0021.00 4.8%  
Dividend yield (eoy) %0.21.3 13.0%  
Book value per share (Unadj.) Rs194.6862.5 22.6%  
Shares outstanding (eoy) m126.20172.56 73.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.33.2 71.1%   
Avg P/E ratio x35.721.5 165.8%  
P/CF ratio (eoy) x19.216.5 116.8%  
Price / Book Value ratio x2.91.8 162.8%  
Dividend payout %6.228.9 21.5%   
Avg Mkt Cap Rs m72,300269,194 26.9%   
No. of employees `00013.34.0 331.5%   
Total wages/salary Rs m6,96017,939 38.8%   
Avg. sales/employee Rs Th2,413.521,190.3 11.4%   
Avg. wages/employee Rs Th523.24,470.1 11.7%   
Avg. net profit/employee Rs Th152.43,120.0 4.9%   
INCOME DATA
Net Sales Rs m32,10685,037 37.8%  
Other income Rs m2262,338 9.7%   
Total revenues Rs m32,33287,374 37.0%   
Gross profit Rs m4,44834,991 12.7%  
Depreciation Rs m1,7303,817 45.3%   
Interest Rs m24120,310 1.2%   
Profit before tax Rs m2,70313,202 20.5%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-100 0.0%   
Tax Rs m6752,281 29.6%   
Profit after tax Rs m2,02812,520 16.2%  
Gross profit margin %13.941.1 33.7%  
Effective tax rate %25.017.3 144.6%   
Net profit margin %6.314.7 42.9%  
BALANCE SHEET DATA
Current assets Rs m17,34087,590 19.8%   
Current liabilities Rs m9,559185,578 5.2%   
Net working cap to sales %24.2-115.2 -21.0%  
Current ratio x1.80.5 384.3%  
Inventory Days Days10031 323.2%  
Debtors Days Days5748 119.6%  
Net fixed assets Rs m20,779108,523 19.1%   
Share capital Rs m252345 73.1%   
"Free" reserves Rs m24,499148,481 16.5%   
Net worth Rs m24,553148,826 16.5%   
Long term debt Rs m3,517144,957 2.4%   
Total assets Rs m39,595482,394 8.2%  
Interest coverage x12.21.7 740.9%   
Debt to equity ratio x0.11.0 14.7%  
Sales to assets ratio x0.80.2 460.0%   
Return on assets %5.76.8 84.2%  
Return on equity %8.38.4 98.2%  
Return on capital %10.512.0 87.8%  
Exports to sales %48.60-   
Imports to sales %14.20-   
Exports (fob) Rs m15,617NA-   
Imports (cif) Rs m4,571NA-   
Fx inflow Rs m15,61715,001 104.1%   
Fx outflow Rs m5,8285,150 113.2%   
Net fx Rs m9,7909,851 99.4%   
CASH FLOW
From Operations Rs m2,764-100,393 -2.8%  
From Investments Rs m-1,432-24,202 5.9%  
From Financial Activity Rs m-1,591135,705 -1.2%  
Net Cashflow Rs m-25911,110 -2.3%  

Share Holding

Indian Promoters % 45.9 52.9 86.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 4.0 285.0%  
FIIs % 25.3 26.6 95.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 16.5 105.5%  
Shareholders   36,892 93,274 39.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   STRIDES SHASUN LTD  ELDER PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Analysis of IPOs Launched in 2018, Governments Effort to Boost Aviation Infrastructure and Key Stocks in Action Today(Pre-Open)

The returns from initial public offers (IPOs) launched in 2018 are mixed. Comparing the gain/ (loss) since the listing date as mentioned in the last column, seven stocks are in the negative territory.

Related Views on News

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jun 21, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS